All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-07-09T14:34:25.000Z

An asparaginase-based pediatric-inspired chemotherapy regimen: outcomes for older patients with Ph- ALL

Jul 9, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL.


Results from a retrospective analysis evaluating outcomes in older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-ALL) treated with a pediatric-inspired protocol have been published in Hematology by Perusini et al.1 The analysis included 73 patients aged ≥ 60 years treated with a modified pediatric-inspired chemotherapy regimen incorporating either pegylated asparaginase (PEG-ASP) or native ASP (EC-ASP) between January 2002 and January 2022.


Key learnings

In older patients receiving a modified pediatric-inspired chemotherapy regimen including PEG-ASP or EC-ASP, 61% of patients experienced Grade III-IV adverse events (AEs); the most prevalent AEs were thrombosis (35.6%), febrile neutropenia (38.4%), and transaminitis (34.2%). 

Median overall survival (OS) was 54 months (95% confidence interval (CI), > 23.7), and the leukemia-free (LFS) survival at 4 years was 48% (95% CI, 33.7–60.6). 

The type of ASP was not significantly associated with OS, LFS or early mortality, but AEs were higher with PEG-ASP vs EC-ASP; male sex and high PEG-ASP dose were identified as significant independent factors for thrombotic events. 

Older age ( 70 years), increased white blood cell count at presentation, previous diagnosis of malignancy, and positive measurable residual disease status post-induction therapy were found to be significantly associated with worse OS. 

An ASP-centered pediatric-inspired chemotherapy protocol can be an effective and well-tolerated therapeutic option for older patients with Ph- ALL when used alongside with diligent monitoring and follow-up. 


  1. Perusini MA, Andrews C, Atenafu EG., et al. Outcomes and adverse events in older acute lymphoblastic leukemia patients treated with a pediatric-inspired protocol with pegylated or native asparaginase. Hematology. 2024:29(1). DOI: 10.1080/16078454.2024.2329027

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox